Display Settings:

Format

Send to:

Choose Destination
    Exp Clin Psychopharmacol. 2002 Aug;10(3):159-61.

    Experimental and clinical psychopharmacology: National Institute on Drug Abuse's clinical research agenda.

    Source

    National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA. aleshner@aaas.org

    Abstract

    Studies of drugs and behavior are a core component of virtually every portfolio within the broad purview of the National Institute on Drug Abuse (NIDA). Moreover, psychopharmacological research is an important vehicle for advancing understanding of how drugs of abuse produce their effects, particularly including addiction. However, as with all major public health issues, simply understanding the issue is not enough. NIDA's psychopharmacology projects, therefore, span basic, clinical, and applied (e.g., medication development) research activities. These include the establishment of a nationwide clinical trials network designed to provide an infrastructure to test both behavioral and psychopharmacological treatments in a real-life practice setting with diverse patients.

    PMID:
    12233978
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for American Psychological Association

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk